Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry

Recruiting

• Conditions: Oligometastasis; Metastatic Cancer

• Registration Number: NCT04085029
• Lead Sponsor: Duke University

Brief Summary

The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-09-09
• Study First Submitted QC: 2019-09-09
• Study First Posted: 2019-09-11
• Study Start: 2019-09-26
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-13
• Last Update Posted: 2024-03-15
• Primary Completion: 2029-09
• Study Completion: 2029-09

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• Age ≥ 18 years of age
• Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment
• Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s)
• Patient must sign study-specific informed consent

Read More

Exclusion Criteria

• None

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Occurrence of acute adverse events following radiotherapy	90 Days

Trial Locations

Locations (5)

Duke Cancer Institute Cary; 🇺🇸 Cary, North Carolina, United States

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States

Duke Women's Cancer Care Raleigh; 🇺🇸 Raleigh, North Carolina, United States

Duke Raleigh Hospital; 🇺🇸 Raleigh, North Carolina, United States

Durham Veterans Administration Health Care System (DVAHCS); 🇺🇸 Durham, North Carolina, United States